Facebook Linkedin Twitter
Inside Precision Medicine Pangea’s Platform Could Increase Patients who Benefit from I/O Therapies by 50%

Cancer transcriptome

Pangea’s Platform Could Increase Patients who Benefit from I/O Therapies by 50%
News & Features

Pangea’s Platform Could Increase Patients who Benefit from I/O Therapies by 50%

Alex Philippidis
0
Quantabio Announces RNA Next-Generation Sequencing Library Preparation Tool
News & Features

Quantabio Announces RNA Next-Generation Sequencing Library Preparation Tool

0
Lung cancer, computer artwork.
Molecular Dx

MSKCC Small Cell Cancer Molecular Atlas IDs Potential Therapy Target

0
Young, male, brain cancer patient wearing a hat/head covering is sitting in bed With a Toy Dog. Image signifies use of precision cancer therapy to improve outcomes.
Molecular Dx

Three-Platform Approach Brings Precision Medicine Closer for Children with Cancer

0
Caris Life Sciences Raises $310M in Financing
Molecular Dx

Caris Life Sciences Raises $310M in Financing

0
Freenome Raises $270M in Series C Financing for Cancer Tests Based on Multiomics Platform
Molecular Dx

Freenome Raises $270M in Series C Financing for Cancer Tests Based on Multiomics Platform

0
Source: Mopic/Fotolia.com
Molecular Dx

New Single Cell Transcriptional Profiling Method Developed

0
Football Buddies
Molecular Dx

Racial Disparities at Transcriptome Level Found for Prostate Cancer

0
Clinical OMICs Magazine Volume 3, Issue No. 4
News & Features

Clinical OMICs Magazine Volume 3, Issue No. 4

0
An increasing number of clinicians are adding the cancer transcriptome to their precision medicine program. They have found that the transcriptome is important in identifying clinically impactful results. [iStock / DeoSum]
Molecular Dx

Deciphering the Cancer Transcriptome

Richard A. Stein, M.D., Ph.D.
0

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine